The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006)

På svenska

Author

  • Henrik Hjorth-Hansen
  • Leif Stenke
  • Stina Soderlund
  • Arta Dreimane
  • Hans Ehrencrona
  • Tobias Gedde-Dahl
  • Bjorn Tore Gjertsen
  • Martin Hoglund
  • Perttu Koskenvesa
  • Kourosh Lotfi
  • Waleed Majeed
  • Berit Markevarn
  • Lotta Ohm
  • Ulla Olsson-Stromberg
  • Kari Remes
  • Merja Suominen
  • Bengt Simonsson
  • Kimmo Porkka
  • Satu Mustjoki
  • Johan Richter
Show all

Summary, in English

We randomised 46 newly diagnosed patients with chronic myeloid leukaemia (median age 56) to receive dasatinib 100mg QD or imatinib 400mg QD and report outcome as an intention-to-treat analysis with 36months follow-up. Early cytogenetic and molecular responses were superior in the dasatinib group, with a tendency that imatinib patients caught up with time. For instance, MR3.0 was reached at 3months in 36% vs. 8% (P=0.02), at 12months in 81% vs. 46% (P=0.02) and at 18months in 73% vs. 65% (n.s.) of the patients in the two groups. In contrast, MR4.5 was consistently superior in the dasatinib group at all time points from 6months onwards, reaching 61% vs. 21% (P<0.05) at 36months. Sixty-four vs. 71% of the patients in the dasatinib and imatinib arms, respectively, remained on assigned drug. Dasatinib dose was frequently reduced, but with maintained excellent effect. One imatinib patient progressed to blastic phase, but no CML-related deaths occurred. In conclusion, our data compare favourably with those of the dasatinib registration study, DASISION. The fast and deep molecular responses induced by dasatinib compared with imatinib may be exploited to increase the proportion of patients who can achieve a treatment-free remission after treatment discontinuation.

Department/s

Publishing year

2015

Language

English

Pages

243-250

Publication/Series

European Journal of Haematology

Volume

94

Issue

3

Document type

Journal article

Publisher

Wiley-Blackwell

Topic

  • Hematology

Keywords

  • dasatinib
  • imatinib
  • randomized controlled trial
  • deep response
  • toxicity

Status

Published

ISBN/ISSN/Other

  • ISSN: 1600-0609